Recent Discovery on tRNA Halves in Prostate Cancer

Tiny pieces of genetic material called tRNA halves play a surprising role in fueling prostate cancer growth, according to new research published in PLOS Biology. These molecules form when normal tRNA, short strands of RNA that help build proteins, get split in half inside cells, especially those driven by male hormones like in prostate cancer. […]

Smart Antibody Medicines: How the ALCO5 Platform Could Upgrade Targeted Cancer Therapy

ALCO5 is a new way of building “smart” cancer drugs that combine an antibody with a powerful medicine in a single, targeted package. The aim is to hit cancer cells much harder while sparing as much healthy tissue as possible, and to do this with drug types that previously could not be used in these […]

Stem Cell Breakthrough Enables Scalable Helper T Cell Therapies

Researchers at the University of British Columbia have achieved a major advance in stem cell engineering by developing a reliable method to produce helper T cells from stem cells in a controlled lab environment. This breakthrough, detailed in the journal Cell Stem Cell, tackles a persistent obstacle in cell therapy production, making treatments more affordable […]

Deciparticle Everolimus: Reviving mTOR Inhibition for Neuroendocrine Prostate Cancer?

Sapu-003, a nanoparticle-formulated version of everolimus delivered via a new platform (Deciparticle) has received approval for first-in-human Phase 1 testing in breast cancer patients, representing a major advance in intravenous oncology drug delivery. Unlike the standard oral everolimus tablet, which achieves only 10-20% bioavailability due to extensive first-pass metabolism and gastrointestinal degradation, the Deciparticle platform […]

ADI-212: Immune Cells Engineered to Beat Advanced Prostate Cancer

ADI-212 is a new type of immune cell therapy made from gamma delta T cells, the kind of immune cells that naturally go after tumors. These cells are specially engineered to attack PSMA-positive metastatic castration-resistant prostate cancer. The therapy has two smart upgrades. First, it carries a special version of IL-12, a powerful immune signal, […]

PSMA-1-DOTA: A New Ligand to Make Prostate Cancer Radioligand Therapy More Targeted

PSMA-targeted radioligand therapy (RLT) has transformed treatment for end-stage prostate cancer, offering strong tumor control in patients who have exhausted other options. However, these therapies frequently cause severe salivary gland damage, leading to debilitating dry mouth that often forces patients to stop treatment early. To overcome this, researchers at Case Western Reserve University developed PSMA-1-DOTA, […]

Dual FOXA1/FOXA2 Targeting to Shut Down Lineage-Plastic Castration-Resistant Prostate Cancer

Targeting FOXA1 and FOXA2 in castration-resistant prostate cancer represents a new way of attacking the disease at the level of its lineage “identity” rather than only at the androgen receptor. FOXA1 and FOXA2 belong to a family of pioneer transcription factors. These pioneer transcription factors unlock tightly packed DNA, creating access for other proteins that […]

KAIST In Situ CAR-Macrophage Therapy

The KAIST team has introduced a highly innovative form of cancer immunotherapy that turns the body’s own macrophages into potent, targeted cancer killers directly inside solid tumours. Instead of the classic, laborious route of extracting immune cells from a patient, engineering them in a lab, expanding them, and reinfusing them, this approach reprograms macrophages already […]

From T Cells to B Cells: The Next Generation of Personalized Cancer Vaccines

A research team at the Korea Advanced Institute of Science and Technology (KAIST) has developed a new artificial intelligence model that could change how personalized cancer vaccines are designed. For decades, most cancer vaccine strategies have focused on training the immune system’s T cells to attack tumors quickly and directly, which can shrink tumors but […]

CRISPR Epigenetic Editing: Safely Reactivating Genes for Sickle Cell and Cancer’s Future

A new form of CRISPR technology developed by researchers at the University of New South Wales (UNSW Sydney) and St Jude Children’s Research Hospital promises a safer path for treating genetic diseases by controlling genes without cutting DNA strands. Published in Nature Communications, the study demonstrates epigenetic editing that removes methyl groups (small chemical clusters […]